Continuous glucose monitoring (CGM) in the pediatric population with type 1 diabetes (T1D) was somewhat infamously described as “satisfaction without success” (1); success with CGM is strongly related to its use, and children and adolescents in some countries seem to be particularly reluctant to use CGM devices regularly as the behavioral changes these devices force on them may not be desirable. However, the SWITCH randomized clinical trial clearly demonstrated that CGM can be as successful in adolescents as in adults with T1D. Despite this fact, the reimbursement for CGM in Europe is still far from universal (2) but growing steadily as data on its benefits accumulate. The use of retrospective (professional) CGM has expanded far beyond its initial indications. Also, type 2 diabetes (T2D) is becoming an important focus for both retrospective and real-time CGM. Finally, an important study demonstrated that the home use of threshold insulin suspend based on sensor-augmented insulin pump therapy in T1D can reduce and prevent hypoglycemia.